CellRapeutics™ CAR-T Engineering Strategies for In Vivo Imaging Detection Service

The Potential of CAR-T Imaging for Cancer Immunotherapy

CAR-T immunotherapy is a robust treatment strategy for hematologic malignancies with dramatic anti-tumor efficacy. However, the expansion and trafficking rate of CAR-T cells are often insufficient to produce long-term remission, and serious CRS toxicities may occur after administration. The imaging platform development for CAR-T cell expansion and trafficking visualization will provide a promising approach to monitor inadequate response and act as an early warning for CAR-T toxicity, allowing CAR-T therapy to be tailored accordingly to maximize therapeutic efficiency.

Fig.1 The schematic of in vivo CAR-T imaging.¹

Our CellRapeutics™ CAR-T Engineering Strategies for In Vivo Imaging Detection Service

To this end, Creative Biolabs is committed to providing comprehensive CAR-T imaging services for global customers to facilitate the tracking of CAR-T cells in vivo. Our services cover non-specific strategies to visualize activated T cells and robust reporter systems to specifically monitor engineered T cells. These approaches are expected to provide valuable information and guidance to improve CAR-T therapy.

The Breadth of Our CAR-T Imaging Service

Our CAR-T imaging services cover a variety of non-specific approaches to detect activated T cells, and many robust reporter systems to specifically monitor engineered T cells, including but not limited to the following sections:

Process diagram

Our comprehensive service workflow is meticulously designed to move your universal CAR candidate from concept to preclinical validation efficiently and reliably.

Final deliverables include a biodistribution report, a QC-certified CAR-T cell bank, and validation confirming stable, safe reporter integration without functional loss.

Contact our team to fully go over your one-of-a-kind requirements.

Our Advantage

• Seamless Translation Support: We provide high-standard quality control tools and comprehensive documentation, ensuring smooth knowledge transfer and enabling your team to confidently transition the engineered cells and imaging protocols into later-stage clinical development.
• End-to-End Strategic Partnership: We offer consultation from design to final in vivo data analysis, ensuring optimal reporter selection and maximizing the scientific and commercial value extracted from every preclinical study.

Related Services

What the Data Say

Fig.2 Photoacoustic images of CAR-T cells visualization labeled with ferumoxytol.²

Frequently Asked Questions

Q1: What is the significance of CAR-T imaging development?

A1: As CAR-T therapy continues to become an important means of cancer treatment, there will be an urgent need to develop several appropriate imaging platforms to allow non-invasive imaging and monitoring of the expansion and trafficking rate of CAR-T cells in vivo. CAR-T cell dynamics visualization is of great significance in studying the interaction between T cells and cancer cells, as well as several normal tissues.

Q2: What criteria should an ideal CAR-T imaging platform meet?

A2: Such a CAR-T imaging platform meets the following criteria:

• The reporter/molecule in the imaging platform should be non-immunogenic;
• When detecting the low quantity of CAR-T cells, the platform should have high sensitivity to image;
• The reporter/molecule of the imaging platform should have low background expression on normal tissue;
• The imaging molecular and imaging process should not affect abnormal CAR-T cell functions.

Work with Creative Biolabs

Fig.3 Work with Creative Biolabs.

Creative Biolabs provides comprehensive in vivo CAR-T imaging services that allow for full customization and design from pilot studies to special targeted projects. If you are interested in more information about our in vivo CAR-T imaging service, please don't hesitate to contact us.

References

1. Sakemura, R.; et al. In vivo CAR-T cell imaging: Paving the way for success in CAR-T cell therapy. Mol Ther Oncolytics. 2021, 20:625-633.
2. Kiru, L.; et al. In vivo imaging of nanoparticle-labeled CAR-T cells. Proc Natl Acad Sci U S A. 2022, 119(6):e2102363119.